-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
L-Chicoric acid
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/70831-56-0.gif)
| Category | HIV Integrase |
| CAS | 70831-56-0 |
| Description | Cichoric acid, that can be isolated from the herbs of Echinacea purpurea, has been shown to inhibit hyaluronidase and HIV-1 integrase, and to possess phagoeytosis stimulatory activity in vitro and in vivo and antiviral acitivy. Chicoric acid may reduce acute alcohol-induced steatosis in mice through interfering with the induction of iNOS and iNOS-dependent signaling cascades in the liver. Chicoric acid also inhibited cell viability and induced apoptosis in 3T3-L1 preadipocytes which was characterized by chromatin condensation and poly ADP-ribose-polymerase (PARP) cleavage. |
Product Information
| Synonyms | (2r,3r)-2,3-bis[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid; (2R,3R)-2,3-BIS[[(2E)-3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPENYL]OXY]-BUTANE DIOIC ACID; CHICHORIC ACID; CICHORIC ACID; CICHORINIC ACID; DICAFFEOYL TARTARIC ACID; L-CHICORIC ACID; Cichoric Acid (Chicoric acid) |
| IUPAC Name | (2R,3R)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid |
| Molecular Weight | 474.37 |
| Molecular Formula | C22H18O12 |
| Canonical SMILES | C1=CC(=C(C=C1C=CC(=O)OC(C(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)C(=O)O)O)O |
| InChI | 1S/C22H18O12/c23-13-5-1-11(9-15(13)25)3-7-17(27)33-19(21(29)30)20(22(31)32)34-18(28)8-4-12-2-6-14(24)16(26)10-12/h1-10,19-20,23-26H,(H,29,30)(H,31,32)/b7-3+,8-4+/t19-,20-/m1/s1 |
| InChIKey | YDDGKXBLOXEEMN-IABMMNSOSA-N |
| Boiling Point | 785.0±60.0 °C at 760 mmHg |
| Flash Point | 272.9±26.4 °C |
| Purity | >98% |
| Density | 1.6±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | White powder |
| Application | Anti-inflammatory |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Storage | Store at -20 °C |
| Complexity | 740 |
| Exact Mass | 474.07982601 |
| Index Of Refraction | 1.726 |
| In Vitro | L-Chicoric Acid inhibits integration at concentrations from 500 nM to 10 μM but also inhibits entry at concentrations above 1 μM. L-Chicoric Acid clearly affects viral entry at concentrations of 5 μM and higher. L-Chicoric Acid also inhibits integration as indicated both by an increased ratio of two LTR circle DNA to cDNA and an accompanying decrease in integrated provirus. The EC50 of L-Chicoric Acid against HIV is approximately 500 nM, a concentration that does not inhibit HIV entry in H9 cells. The ED50 of L-Chicoric Acid against HIVNL4-3 control virus is 400 nM, while HIVNL4-3 passaged in the presence of 8 μM L-Chicoric Acid is completely resistant to the compound. |
| PSA | 208.12000 |
| Target | IC50: ~100 nM (HIV-1 integrase) HIV-1 |
| Vapor Pressure | 0.0±2.9 mmHg at 25°C |
| XLogP3-AA | 2 |
